Evogene (EVGN) has released an update.
Evogene Ltd. announced significant changes to its management team, including the departure of Chief Technology Officer Mr. Mark Kapel, who will continue as a consultant post-termination. The company will redistribute Kapel’s duties between VP Computational Platform Dr. Ilia Zhidkov and VP Experimental Research Center Dr. Silvia Shaked. Additionally, Evogene has appointed Dr. Gabi Tarcic, formerly of Fore Biotherapeutics, as the new VP Product effective September 22, 2024.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
